伐努赛珠单抗

伐努赛珠单抗INN:Vanucizumab;开发代号:RG7221)是一种实验性人源化单克隆抗体,设计用于治疗癌症[1][2]

伐努赛珠单抗
单克隆抗体
种类完整抗体
目标血管生成素2
临床资料
其他名称RG7221
ATC码
  • 未分配
识别信息
CAS号1448221-05-3
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6529H10033N1733O2038S46
摩尔质量146,887.94 g·mol−1

伐努赛珠单抗是一种双特异性单克隆抗体,由两条不同的重链和两条不同的轻链组成。该抗体的一个臂结合血管生成素2(Ang2),另一个臂基于贝伐珠单抗(Avastin),结合血管内皮生长因子A(VEGF-A)。该抗体旨在同时抑制VEGF-A和 Ang2,与单独抑制VEGF-A相比,可提供更优异的临床益处。[3]

该药物由基因泰克/罗氏公司开发。

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab页面存档备份,存于互联网档案馆), American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2) [2023-12-28]. (原始内容存档 (PDF)于2020-08-15). 
  3. ^ Bendell, Johanna C.; Sauri, Tamara; Gracián, Antonio Cubillo; Alvarez, Rafael; López‐López, Carlos; García‐Alfonso, Pilar; Hussein, Maen; Miron, Maria‐Luisa Limon; Cervantes, Andrés; Montagut, Clara; Vivas, Cristina Santos. The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). The Oncologist. 2020-3, 25 (3). ISSN 1083-7159. PMC 7066709 . PMID 32162804. doi:10.1634/theoncologist.2019-0291.